Core Insights - Lantheus Holdings, Inc. (NASDAQ:LNTH) is recognized as one of the seven cheap pharmaceutical stocks to buy according to hedge funds, ranking fourth on the list [2] - TD Cowen has lowered its price target for LNTH from $80 to $75 while maintaining a Buy rating, reflecting adjustments in their financial model ahead of the company's fourth-quarter results [2][8] - The company has completed the divestiture of its Single Photon Emission Computed Tomography (SPECT) business to SHINE Technologies, which may allow it to focus on more profitable growth areas [3] Company Strategy - Lantheus is prioritizing the growth of its commercial portfolio in PET radiodiagnostics and microbubble products for contrast-enhanced ultrasound procedures [4] - The company plans to invest in and develop its pipeline of radiopharmaceuticals to support long-term growth in precision imaging and targeted treatments [4] - Lantheus aims to leverage its expertise in nuclear medicine to create innovative diagnostic and therapeutic solutions for patients [4][5]

Core Viewpoint - Lantheus Holdings has successfully completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, allowing the company to concentrate on its PET radiodiagnostics and microbubbles portfolio while advancing its pipeline of radiopharmaceuticals [1] Group 1 - Lantheus has divested its SPECT business, which includes diagnostic agents and manufacturing operations located in North Billerica, Massachusetts, as well as related operations in Canada [1] - The divestiture aligns with Lantheus' strategy to focus on its growing commercial portfolio and enhance its research and development efforts in radiopharmaceuticals [1]